Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: A novel epigenetic-targeting approach in acute myeloid leukemia

Histone deacetylase (HDAC) inhibitors either alone or in combination with hypomethylating agents have limited clinical effect in acute myeloid leukemia (AML). Previously we demonstrated that AML patients with higher miR-29b expression had better response to the hypomethylating agent decitabine. Ther...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Mims, Alice, Walker, Alison R., Huang, Xiaomeng, Sun, Jin, Wang, Hongyan, Santhanam, Ramasamy, Dorrance, Adrienne M., Walker, Chris, Hoellerbauer, Pia, Tarighat, Somayeh S., Chan, Kenneth K., Klisovic, Rebecca B., Perrotti, Danilo, Caligiuri, Michael A., Byrd, John C., Chen, Ching-Shih, Lee, L. James, Jacob, Samson, Mrózek, Krzysztof, Bloomfield, Clara D., Blum, William, Garzon, Ramiro, Schwind, Sebastian, Marcucci, Guido
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2012
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3764604/
https://ncbi.nlm.nih.gov/pubmed/23178755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2012.342
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak